39631 recent Wall Street rating changes — with our own star rating shown next to every analyst we independently track.
Track the latest analyst rating changes from Wall Street brokerages: stock upgrades, downgrades and price-target revisions, updated through the day. Unlike a plain ratings feed, every change here is matched — where we can — to the analyst's independent track record on 13Foresight, so you can see at a glance whether the person behind the call has actually been accurate. Analysts we rank show a ★★★★☆ score and link to their full performance page; firms link to their pooled track record. Use the tabs below to filter by change type.
| When | Stock | Change | Analyst | Rating | Price Target |
|---|---|---|---|---|---|
|
Sep 16
00:12 UTC
|
LIF
Life360
|
◎ Target | Wyatt Swanson ★★★★☆ #784 | Neutral | $47.00→ $40.00-14.9% |
|
Sep 16
00:12 UTC
|
KRP
Kimbell Royalty
|
◎ Target | Tim Rezvan ★★☆☆☆ #2560 | Overweight | $17.00→ $18.00+5.9% |
|
Sep 16
00:12 UTC
|
KIST
Kistos
|
◎ Target | firm only | Buy | GBX 325→ GBX 405+24.6% |
|
Sep 16
00:12 UTC
|
IVA
Inventiva
|
◎ Target | Seamus Fernandez ★★★☆☆ #1360 | Buy | $11.00→ $14.00+27.3% |
|
Sep 16
00:12 UTC
|
IRT
Independence Realty Trust
|
◎ Target | Ami Probandt ★★★☆☆ #2099 | Buy | $19.00→ $18.00-5.3% |
|
Sep 16
00:12 UTC
|
IONS
Ionis Pharmaceuticals
|
◎ Target | Brad Canino not yet tracked | Buy | $89.00→ $80.00-10.1% |
|
Sep 16
00:12 UTC
|
INTC
Intel
|
◎ Target | Ivan Feinseth ★★☆☆☆ #2274 | Buy | $118.00→ $145.00+22.9% |
|
Sep 16
00:12 UTC
|
IMMX
Immix Biopharma
|
◎ Target | Graig Suvannavejh ★★☆☆☆ #2635 | Outperform | $15.00→ $26.00+73.3% |
|
Sep 16
00:12 UTC
|
HMSO
Hammerson
|
◎ Target | firm only | Buy | GBX 448→ GBX 423-5.6% |
|
Sep 16
00:12 UTC
|
GTX
Garrett Motion
|
◎ Target | Rajat Gupta not yet tracked | Overweight | $37.00→ $35.00-5.4% |
|
Sep 16
00:12 UTC
|
GSK
GSK
|
◎ Target | firm only | Hold | GBX 2,000→ GBX 2,200+10.0% |
|
Sep 16
00:12 UTC
|
GLW
Corning
|
◎ Target | John Roberts not yet tracked | Outperform | $210.00→ $180.00-14.3% |
|
Sep 16
00:12 UTC
|
FTK
Flotek Industries
|
◎ Target | Robert Brown ★★★☆☆ #2224 | Buy | $40.00→ $44.00+10.0% |
|
Sep 16
00:12 UTC
|
FTI
TechnipFMC
|
◎ Target | Scott Gruber ★★★☆☆ #2072 | Buy | $80.00→ $85.00+6.2% |
|
Sep 16
00:12 UTC
|
EXOD
Exodus Movement
|
◎ Target | Andrew Harte ★★★☆☆ #1729 | Buy | $16.00→ $12.00-25.0% |
|
Sep 16
00:12 UTC
|
ET
Evertz Technologies
|
◎ Target | firm only | Sec→ r Perform | C$17.00→ C$16.00-5.9% |
|
Sep 16
00:12 UTC
|
ET
Evertz Technologies
|
◎ Target | firm only | Outperform | C$18.00→ C$16.50-8.3% |
|
Sep 16
00:12 UTC
|
ET
Evertz Technologies
|
◎ Target | firm only | Outperform | C$18.00→ C$17.00-5.6% |
|
Sep 16
00:12 UTC
|
EOSE
Eos Energy Enterprises
|
◎ Target | Sean Milligan ★★☆☆☆ #2516 | Buy | $11.00→ $10.00-9.1% |
|
Sep 16
00:12 UTC
|
ENVA
Enova International
|
◎ Target | David Scharf ★★★☆☆ #1879 | Market Outperform | $270.00→ $215.00-20.4% |
|
Sep 16
00:12 UTC
|
ENVA
Enova International
|
◎ Target | Moshe Orenbuch ★★★★☆ #822 | Buy | $257.00→ $220.00-14.4% |
|
Sep 16
00:12 UTC
|
ENB
Enbridge
|
◎ Target | firm only | Outperform | C$83.00→ C$84.00+1.2% |
|
Sep 16
00:12 UTC
|
ENB
Enbridge
|
◎ Target | firm only | Market Perform | C$79.00→ C$80.00+1.3% |
|
Sep 16
00:12 UTC
|
ELMT
Elmet Group
|
◎ Target | James Ricchiuti ★★★☆☆ #1284 | Buy | $21.00→ $25.00+19.0% |
|
Sep 16
00:12 UTC
|
ELF
e.l.f. Beauty
|
◎ Target | Anna Lizzul ★★★☆☆ #1121 | Buy | $100.00→ $118.00+18.0% |
|
Sep 16
00:12 UTC
|
DT
Dynatrace
|
◎ Target | Keith Bachman ★★★★★ #258 | Outperform | $60.00→ $62.00+3.3% |
|
Sep 16
00:12 UTC
|
DRI
Darden Restaurants
|
◎ Target | Brian Bittner ★★★☆☆ #1838 | Outperform | $235.00→ $245.00+4.3% |
|
Sep 16
00:12 UTC
|
DFTX
Definium Therapeutics
|
◎ Target | Christopher Chen not yet tracked | Outperform | $75.00→ $79.00+5.3% |
|
Sep 16
00:12 UTC
|
DATA
GlobalData
|
◎ Target | firm only | Neutral | GBX 110→ GBX 90-18.2% |
|
Sep 16
00:12 UTC
|
DATA
GlobalData
|
◎ Target | firm only | Buy | GBX 105→ GBX 90-14.3% |
|
Sep 16
00:12 UTC
|
CTNM
Contineum Therapeutics
|
◎ Target | Joel Beatty ★★★★☆ #615 | Outperform | $20.00→ $19.00-5.0% |
|
Sep 16
00:12 UTC
|
CTNM
Contineum Therapeutics
|
◎ Target | Debanjana Chatterjee ★★☆☆☆ #2371 | Buy | $26.00→ $24.00-7.7% |
|
Sep 16
00:12 UTC
|
CSR
Centerspace
|
◎ Target | firm only | Neutral | $70.00→ $68.00-2.9% |
|
Sep 16
00:12 UTC
|
CSHR
CoinShares
|
◎ Target | Alex Bond ★★★☆☆ #2216 | Outperform | $7.00→ $9.00+28.6% |
|
Sep 16
00:12 UTC
|
CMS
CMS Energy
|
◎ Target | Julien Dumoulin-Smith not yet tracked | Hold | $78.00→ $74.00-5.1% |
|
Sep 16
00:12 UTC
|
CLLS
Cellectis
|
◎ Target | Jack Allen ★★★★★ #207 | Outperform | $10.00→ $8.00-20.0% |
|
Sep 16
00:12 UTC
|
CLLS
Cellectis
|
◎ Target | Yanan Zhu ★★☆☆☆ #2322 | Equal Weight | $4.00→ $3.00-25.0% |
|
Sep 16
00:12 UTC
|
CHYM
Chime Financial
|
◎ Target | Will Nance ★★★★☆ #722 | Buy | $33.00→ $37.00+12.1% |
|
Sep 16
00:12 UTC
|
CGX
Cineplex
|
◎ Target | firm only | Outperform | C$14.00→ C$15.00+7.1% |
|
Sep 16
00:12 UTC
|
CER
Cerillion
|
◎ Target | firm only | Buy | GBX 1,400→ GBX 1,200-14.3% |
|
Sep 16
00:12 UTC
|
CCL
Carnival
|
◎ Target | Chris Woronka ★★★☆☆ #1177 | Hold | $34.00→ $29.00-14.7% |
|
Sep 16
00:12 UTC
|
CAKE
Cheesecake Factory
|
◎ Target | Zachary Fadem ★★★☆☆ #2098 | Equal Weight | $90.00→ $105.00+16.7% |
|
Sep 16
00:12 UTC
|
BWIN
Baldwin Insurance Group
|
◎ Target | Charlie Lederer ★★★★☆ #651 | Market Perform | $26.00→ $32.50+25.0% |
|
Sep 16
00:12 UTC
|
BNTC
Benitec Biopharma
|
◎ Target | Yun Zhong ★★☆☆☆ #2386 | Outperform | $16.00→ $17.00+6.2% |
|
Sep 16
00:12 UTC
|
BLKB
Blackbaud
|
◎ Target | Rob Oliver not yet tracked | Outperform | $54.00→ $58.00+7.4% |
|
Sep 16
00:12 UTC
|
BKV
BKV
|
◎ Target | Betty Jiang ★★★☆☆ #1256 | Overweight | $36.00→ $35.00-2.8% |
|
Sep 16
00:12 UTC
|
BCE
BCE
|
◎ Target | firm only | Buy | C$37.00→ C$40.00+8.1% |
|
Sep 16
00:12 UTC
|
BBNX
Beta Bionics
|
◎ Target | Travis Steed ★★★☆☆ #1076 | Neutral | $18.00→ $20.00+11.1% |
|
Sep 16
00:12 UTC
|
BBNX
Beta Bionics
|
◎ Target | Jeff Johnson ★★☆☆☆ #2646 | Neutral | $14.00→ $16.00+14.3% |
|
Sep 16
00:12 UTC
|
BARC
Barclays
|
◎ Target | firm only | Overweight | GBX 610→ GBX 620+1.6% |
An analyst rating change is when a Wall Street brokerage updates its recommendation on a stock — an upgrade (e.g. Hold → Buy), a downgrade (e.g. Buy → Sell), or a price-target revision (raising or lowering the expected share price). This page lists the most recent changes across U.S. markets.
Where we independently track the analyst, each change shows our own star rating and accuracy rank, computed from real historical price performance — not the brokerage's own marketing. That lets you judge whether the analyst behind a call has actually been right before.
The feed refreshes several times a day, so new upgrades, downgrades and price-target changes appear the same day they are published. Each row shows the date and time we recorded it.
No. A rating change is one analyst's opinion, not investment advice. Track records vary widely — which is exactly why we attach each analyst's independent accuracy. Always do your own research.